Free tool
FAERS Monitor: Reblozyl
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761136 or its brand name (Reblozyl, Luspatercept-Aamt). Reports on generic versions are filed under their own applications.
Reports
2,614
Serious
1,604
61% of reports
Hospitalization
568
Death reported
414
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death244
- off label use193
- haemoglobin decreased144
- fatigue137
- drug ineffective114
- weight decreased92
- product storage error85
- dizziness84
- myelodysplastic syndrome75
- dyspnoea73
- fall70
- asthenia57
- weight increased56
- pneumonia55
- diarrhoea51
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 142 |
| 2021 | 248 |
| 2022 | 440 |
| 2023 | 325 |
| 2024 | 494 |
| 2025 | 536 |
| 2026 | 424 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,545 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| myelodysplastic syndromeSignal | 75 | 41.9 | 33.5 | 2,943 |
| haemoglobin decreasedSignal | 144 | 11.3 | 9.6 | 1,346 |
| product storage errorSignal | 85 | 7.8 | 6.3 | 500 |
| weight decreasedSignal | 92 | 2.7 | 2.2 | 94 |
| deathSignal | 244 | 2.3 | 2.0 | 181 |
| weight increasedSignal | 56 | 2.0 | 1.6 | 28 |
| off label use | 193 | 1.8 | 1.5 | 67 |
| fall | 70 | 1.7 | 1.3 | 19 |
| fatigue | 137 | 1.4 | 1.2 | 17 |
| pneumonia | 55 | 1.4 | 1.1 | 5 |
| dizziness | 84 | 1.4 | 1.1 | 8 |
| asthenia | 57 | 1.2 | 0.9 | 2 |
| dyspnoea | 73 | 1.0 | 0.8 | 0 |
| drug ineffective | 114 | 0.7 | 0.6 | 16 |
| diarrhoea | 51 | 0.6 | 0.5 | 11 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.